StockData
Liquidia Corp logo

Liquidia Corp (LQDA) company profile

LQDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3075% above fair value
$56.73+0.36 (+0.64%)

Close on Nov 17, 2026Market cap $5.08BP/E 40.8Yield –

About Liquidia

Pharmaceutical Preparations, SIC 2834

Liquidia is a biopharmaceutical company that develops, manufactures, and commercializes treatments for patients with severe respiratory and vascular diseases, focusing on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company’s primary offerings include Yutrepia, an inhaled dry-powder treprostinil therapy, and a generic treprostinil injection marketed in partnership with Sandoz. Liquidia promotes its products to healthcare professionals, notably pulmonologists and cardiologists, as well as specialty pharmacies and medical distributors.

The company operates primarily within the United States, where it maintains a targeted commercial sales force calling on specialized medical centers. Liquidia conducts manufacturing and research operations at a 45,000-square-foot facility in Morrisville, North Carolina, and holds a lease for an additional 70,131-square-foot site in Morrisville. Globally, the company conducts clinical trials across more than 100 sites in at least 20 countries.

Summary of the business section of Liquidia's latest annual report, written by StockData.

Company profile

Company

Legal name
Liquidia Corp
Founded
2004
Headquarters
Morrisville, NC
Address
419 Davis Drive, Suite 100 27560
Phone
(919) 328-4400
Employees
216, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Raleigh, North Carolina

Stock & identifiers

Ticker
LQDA
Exchange
Nasdaq
IPO date
Jul 26, 2018
Shares outstanding
90M, Jul 29, 2026
Public float
$847.01M, Jun 30, 2025
Filer category
Non-accelerated filer
SEC CIK
1819576
CUSIP
53635D202
ISIN
US53635D2027
FIGI
BBG001J2P905
Share class FIGI
BBG001V0GFD7
LEI
549300O826O5VQJTG707
EIN
85-1710962

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Roger JeffsChief Executive Officer, Director2,167,515
Jason AdairChief Business Officer177,269
Dana BoyleChief Accounting Officer164,028
Russell SchundlerGeneral Counsel617,341
Rajeev SaggarChief Medical Officer141,467
Michael KasetaCFO and COO340,148
Sanjeev KhindriChief Development Officer64,846
Sarah KreppChief Human Resource Officer115,241
Scott MoomawChief Commercial Officer181,487
Stephen M. BlochDirector104,570
Raman SinghDirector53,105
Katherine Rielly-GauvinDirector56,364
Arthur S. KirschDirector46,637
Paul B. ManningDirector673,878
Partners LP CaliganDirector8,163,229
Joanna HorobinDirector39,637
Damian deGoaDirector92,353
David Edward JohnsonDirector8,157,347

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.71M$34.95M$2.81M$708$121
FY2024$6.75M$6.24M$3.32M$241$91
FY2023$4.89M$15.46M$2.24M$247$92
FY2022$10.76M$13.89M$1.76M$131$89

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Roger A. Jeffs
Chief Executive Officer
$824.00K$25.00K$5.59M$1.25M$18.34K$7.71M+14%
Michael Kaseta
Chief Financial Officer and Chief Operating Officer (4)
$592.25K$25.00K$2.75M$772.80K$16.02K$4.16M+10%
Russell Schundler
General Counsel and Secretary
$540.75K$25.00K$2.50M$588.00K$17.35K$3.67M+28%
Rajeev Saggar
Chief Medical Officer
$539.35K$25.00K$1.75M$586.48K$16.02K$2.92M+36%
Scott Moomaw
Chief Commercial Officer
$449.90K$25.00K$1.70M$489.22K$16.84K$2.68M+45%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 216 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?